Literature DB >> 7995394

Home versus hospital intravenous antibiotic therapy in the treatment of young adults with cystic fibrosis.

M N Pond1, M Newport, D Joanes, S P Conway.   

Abstract

We wanted to investigate whether home intravenous antibiotic treatment of pulmonary exacerbations of cystic fibrosis is as effective as treatment in hospital. The case records of all patients attending the Leeds adult cystic fibrosis clinic were reviewed to identify those who had received home intravenous antibiotic treatment. All home treatments undertaken were included. For each home treatment, the temporally closest hospital treatment for that patient was then selected for comparison and the changes with treatment in peak expiratory flow rate (PEFR), forced vital capacity (FVC), forced expiratory volume in one second (FEV1), C-reactive protein (CRP), plasma viscosity, total white cell count, absolute neutrophil count, total immunoglobulin G (IgG) concentration, chest X-ray score (Northern), clinical score, Shwachman-Kulczyki score and weight were analysed for differences between home treatment and hospital treatment. Fifty one paired home/hospital treatments in 25 patients were compared. The improvement in total white cell count was found to be significantly greater in the hospital group, but the difference was very small. The improvements in absolute neutrophil count, and all the other measured variables, were the same in the two groups. Treatment of exacerbations of cystic fibrosis at home or in hospital is, thus, equally effective given proper patient selection and adequate monitoring of the response to treatment.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7995394     DOI: 10.1183/09031936.94.07091640

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  20 in total

1.  Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes.

Authors:  J Michael Collaco; Deanna M Green; Garry R Cutting; Kathleen M Naughton; Peter J Mogayzel
Journal:  Am J Respir Crit Care Med       Date:  2010-06-25       Impact factor: 21.405

Review 2.  Cost-effective treatment of lower respiratory tract infections.

Authors:  J C Garrelts; A M Herrington
Journal:  Pharmacoeconomics       Date:  1996-07       Impact factor: 4.981

3.  An audit of the effect of intravenous antibiotic treatment on spirometric measures of pulmonary function in cystic fibrosis.

Authors:  J M Bradley; E S Wallace; J S Elborn; J L Howard; M P McCoy
Journal:  Ir J Med Sci       Date:  1999 Jan-Mar       Impact factor: 1.568

4.  [Cost comparison of hospital and ambulatory i.v. therapy in adult cystic fibrosis patients. Results of a controlled prospective study].

Authors:  C Krauth; R Busse; C Smaczny; G Ullrich; T O Wagner; J Weber; T Welte
Journal:  Med Klin (Munich)       Date:  1999-10-15

Review 5.  Pharmacoeconomic considerations in the ambulatory use of parenteral cephalosporins.

Authors:  A D Tice
Journal:  Drugs       Date:  2000       Impact factor: 9.546

Review 6.  Ambulatory use of parenteral antibacterials: contemporary perspectives.

Authors:  J E Leggett
Journal:  Drugs       Date:  2000       Impact factor: 9.546

7.  [Economic aspects in treatment of cystic fibrosis with chronic pulmonary pseudomonas infection. Ambulatory intravenous therapy in comparison with inpatient treatment].

Authors:  J M Graf von der Schulenburg; W Greiner; U Klettke; U Wahn
Journal:  Med Klin (Munich)       Date:  1997-10-15

Review 8.  Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies.

Authors:  Christian Krauth; Noushin Jalilvand; Tobias Welte; Reinhard Busse
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 9.  Quality of life in children and adolescents with cystic fibrosis: implications for optimizing treatments and clinical trial design.

Authors:  Janice Abbott; Louise Gee
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

10.  Home intravenous antibiotic treatment for acute pulmonary exacerbations in cystic fibrosis - Is it good for the patient?

Authors:  Iara Maria Sequeiros; Nabil A Jarad
Journal:  Ann Thorac Med       Date:  2009-07       Impact factor: 2.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.